Compass Therapeutics, Inc. — Director's Dealing 2025

Feb 13, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2025-02-11

Reporting Person: Boylan James P (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-11	Stock Option (Right to Buy)	$3.65	A	40000	Acquired	2035-02-11	Common Stock (40000)	Direct

Footnotes

F1: The options vest over 48 substantially equal monthly installments starting March 11, 2025.

F2: The Reporting Person is a member of Enavate Sciences, LP ("Enavate"). Pursuant to an agreement with Enavate, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Enavate, which will in turn ensure that such securities or economic benefits are provided to Enavate.